Evidence map›Paper›PMID 41559121›Full record

ArticleScientific reports2026

Hyperpolypharmacy in patients with chronic kidney disease and its impact on clinical outcomes.

Agathe Mouheb, Marie Metzger, Natalia Alencar de Pinho, Christian Jacquelinet, Maurice Laville, Ziad A Massy, Sophie Liabeuf, Solène M Laville, CKD-REIN STUDY GROUP

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Agathe MouhebPharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, 80054, Amiens, France.
Marie MetzgerCentre for Research in Epidemiology and Population Health (CESP), INSERM UMRS 1018, Paris-Saclay University, Paris Sud University, Versailles Saint Quentin University, 94807, Villejuif, France.
Natalia Alencar de PinhoCentre for Research in Epidemiology and Population Health (CESP), INSERM UMRS 1018, Paris-Saclay University, Paris Sud University, Versailles Saint Quentin University, 94807, Villejuif, France.
Christian JacquelinetCentre for Research in Epidemiology and Population Health (CESP), INSERM UMRS 1018, Paris-Saclay University, Paris Sud University, Versailles Saint Quentin University, 94807, Villejuif, France.
Maurice LavilleCarMeN INSERM 1060, Université de Lyon, 69008, Lyon, France.
Ziad A MassyCentre for Research in Epidemiology and Population Health (CESP), INSERM UMRS 1018, Paris-Saclay University, Paris Sud University, Versailles Saint Quentin University, 94807, Villejuif, France.
Sophie LiabeufPharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, 80054, Amiens, France. liabeuf.sophie@chu-amiens.fr.
Solène M LavillePharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, 80054, Amiens, France.
CKD-REIN STUDY GROUP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperpolypharmacy (≥ 10 daily medications) is frequent in patients with chronic kidney disease (CKD), but its impact remains poorly characterized. This study, based on 3,011 non-dialyzed, non-transplant CKD outpatients from the CKD-REIN cohort (eGFR < 60 mL/min/1.73 m

Indexed as

Drug-Related Side Effects and Adverse ReactionsPolypharmacyRenal Insufficiency, ChronicAgedFemaleGlomerular Filtration RateHospitalizationHumansMaleMiddle AgedRenal Replacement TherapyAdverse outcomesChronic kidney diseaseHyperpolypharmacy

Identifiers

PMID41559121
PMCPMC12824231

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.